Heart failure & cardiomyopathies
Calcium Channel Blockers and Clinical Outcomes in Patients with Continuous-Flow Left Ventricular Assist Devices
Authors' conclusion
In patients with LVAD, CCB therapy fails to show benefits in long-term survival and is associated with increased incidences of neurological dysfunction, bleeding, renal dysfunction, and rehospitalization.
Study context
- Population
- Adults alive with continuous-flow left ventricular assist device (LVAD) at 6 months after implantation, Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006–2017
- Participants
- 10,717 participants
- Exposure
- CCB vs no CCB at 6 months after LVAD implantation
- CCBn = 1,369
- Outcome
- Long-term mortality (5 year survival)
- Follow-up
- 5 years
Methodological detailsregistry-based (INTERMACS)
- Registry-based (INTERMACS)
Main finding
As reported in the abstract
5 year survival
CCB vs No CCBEstimate (95% CI)P value
Adjusted Cox regression, long-term mortality
HR 1.03(0.91–1.17)
P = 0.624Adjusted competing risk regression
SHR 1.07(0.95–1.22)
P = 0.260Observational data: associations, not effects.
Further findings
| Outcome | Estimate | P value | |
|---|---|---|---|
| Long-term mortality, time-varying modelsCCBvs No CCB | HR 0.97 (95% CI 0.87–1.09) | P = 0.682 | |
| Long-term mortality, time-varying modelsCCBvs No CCB | SHR 1.05 (95% CI 0.94–1.18) | P = 0.359 | |
| 0.512Ratio (log scale) |
Mortality by device strategy (subgroup) and propensity-matched analyses
- Null association remained
Original publication
Calcium Channel Blockers and Clinical Outcomes in Patients with Continuous-Flow Left Ventricular Assist Devices. ESC Heart Fail. Published 15 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →